Novavax to explore combined influenza/Covid-19 vaccine for use post pandemic
Reuters | Reuters| Posted by Susmita Pakrasi
Published on: Oct 13, 2020 07:04 PM IST
The flu vaccine, NanoFlu, met the primary and secondary goals in late-stage comparison study with Sanofi’s influenza vaccine Fluzone Quadrivalent earlier in the year.
Novavax Inc said on Tuesday it has set up a team of company veterans as it seeks U.S. regulatory approval for its seasonal influenza vaccine and to help develop a combined influenza/Covid-19 vaccine for use after the pandemic.
The flu vaccine, NanoFlu, met the primary and secondary goals in late-stage comparison study with Sanofi’s influenza vaccine Fluzone Quadrivalent earlier in the year.
Novavax is among global drugmakers racing to develop a vaccine for Covid-19 and last month started a late-stage trial of its experimental vaccine, NVX-CoV2373, in the United Kingdom.
NVX-CoV2373 is also being tested in two ongoing mid-stage trials that began in August.
Get the latest headlines from US news and global updates from Pakistan, Nepal, UK, Bangladesh, and Russia get all the latest headlines in one place with including Nepal Protest and Charlie Kirk Funeral Liveon Hindustan Times.
Get the latest headlines from US news and global updates from Pakistan, Nepal, UK, Bangladesh, and Russia get all the latest headlines in one place with including Nepal Protest and Charlie Kirk Funeral Liveon Hindustan Times.
